Highlights in Earning Call:
1.As of December 31 2020, we had $116.7 million in cash and cash equivalents, which includes the $109 million in gross proceeds raised in fourth quarter of 2020, we believe these funds will be sufficient to support our operations into 2023, 48.8 million shares of common stock outstanding.
2.New acting CMO, Edwina Baskin-Bey.
3.Clinical data update for Phase I/II trial of cirmtuzumab plus ibrutinib for patients with MCL and CLL in 2021 Q2.
4.Clinical data update for Phase Ib of cirmtuzumab plus paclitaxel in patients with HER2 negative breast cancer in 2021 Q2.
5.Preclinical data update for ROR1 expressing tumours in 2021 Q2.
6.First patient with our ROR1 CAR-T cell therapy in 2021 H2.
7.Clinical data update for Phase I/II trial as TK216 for patients with relapsed or refractory Ewing sarcoma in 2021 Q2.
8.Preclinical data in additional ETS driven tumors in 2021 Q2.